Featured Research

from universities, journals, and other organizations

Infants With Bronchiolitis May Benefit More From Albuterol

Date:
May 17, 2007
Source:
Elsevier Health Sciences
Summary:
Bronchiolitis, a wheezing much like asthma in adults, is responsible for many hospital admissions of infants. There are two drugs in general use to treat this condition, epinephrine and albuterol, and there is some controversy and passion involved in the choice of medication. In a new article a double-blind randomized clinical trial involving over 700 infants showed a clear advantage for albuterol.

Bronchiolitis, a wheezing much like asthma in adults, is responsible for many hospital admissions of infants. It is the commonest cause of hospital admission in this age group. There are two drugs in general use to treat this condition, epinephrine and albuterol, and there is some controversy and passion involved in the choice of medication.

In a paper to be presented at the 2007 Society for Academic Emergency Medicine (SAEM) Annual Meeting, a double-blind randomized clinical trial involving over 700 infants over a three year period showed a clear advantage for albuterol in successful discharges from the Emergency Department.

Although many smaller studies have shown either no difference or an advantage to epinephrine, this surprising result of a small but real advantage in using albuterol may force physicians to reassess their treatment choices. Principal Investigaor, Paul Walsh, MD, originally preferred epinephrine prior to conducting this study. The other investigators were Kemedy McQuillan MD, John Caldwel Pharm Dl and Stephen J Rothenberg PhD.

The presentation is entitled "A Double Blind Randomized Controlled Trial Comparing Nebulized Epinephrine And Albuterol In The Emergency Department Treatment Of Bronchiolitis" by Paul Walsh MD, of the Kern Medical Center, Bakersfield & David Geffen School of Medicine at the UCLA, Los Angeles, CA. This paper will be presented at the 2007 SAEM Annual Meeting, May 16-19, 2007, Chicago, IL. Abstracts of the papers presented are published in Volume 14, Issue 5S, the May 2007 supplement of the official journal of the SAEM, Academic Emergency Medicine.


Story Source:

The above story is based on materials provided by Elsevier Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

Elsevier Health Sciences. "Infants With Bronchiolitis May Benefit More From Albuterol." ScienceDaily. ScienceDaily, 17 May 2007. <www.sciencedaily.com/releases/2007/05/070516071538.htm>.
Elsevier Health Sciences. (2007, May 17). Infants With Bronchiolitis May Benefit More From Albuterol. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/05/070516071538.htm
Elsevier Health Sciences. "Infants With Bronchiolitis May Benefit More From Albuterol." ScienceDaily. www.sciencedaily.com/releases/2007/05/070516071538.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins